Iovance Biotherapeutics Inc. Common Stock vs Charles Schwab Corporation Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 27.7× Iovance Biotherapeutics Inc. Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| IOVA | SCHW | |
|---|---|---|
Market Cap | $6.04B | $167.52B |
Volume | 14,805,993 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $14.82 | $113.65 |
52-Week Low | $1.81 | $85.35 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $5.97B | $153.97B |
Dividend Yield | — | 1.32% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Charles Schwab (SCHW) trades at $96.70, up 1.17% with bearish technical signals but strong fundamentals. The company reported record quarterly revenue of $7.08 billion (The Motley Fool, 2026-09-29) and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.33 price target, representing 24% upside potential. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships with Anthropic.
SCHW offers compelling value with a P/E of 17.64 and robust 38.79% net margin, though technical indicators signal near-term caution. The stock faces risks from narrowing interest spreads and market volatility, but strong earnings momentum and institutional support provide solid foundation for long-term growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →